Rubius Therapeutics’ (NASDAQ:RUBY) quiet period will expire on Monday, August 27th. Rubius Therapeutics had issued 10,483,000 shares in its initial public offering on July 18th. The total size of the offering was $241,109,000 based on an initial share price of $23.00. During Rubius Therapeutics’ quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of equities research analysts have issued reports on RUBY shares. JPMorgan Chase & Co. started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued an “overweight” rating on the stock. Morgan Stanley started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued an “overweight” rating and a $37.00 price target on the stock. Leerink Swann started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued an “outperform” rating on the stock. Finally, Jefferies Financial Group started coverage on shares of Rubius Therapeutics in a report on Monday, August 13th. They issued a “buy” rating and a $40.00 price target on the stock.

NASDAQ:RUBY opened at $21.30 on Monday. Rubius Therapeutics has a 12 month low of $19.78 and a 12 month high of $33.01.

In related news, Director Francis M. Cuss bought 10,000 shares of the company’s stock in a transaction dated Friday, July 20th. The stock was purchased at an average cost of $23.00 per share, with a total value of $230,000.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Rubius Therapeutics Company Profile

There is no company description available for Rubius Therapeutics Inc

Featured Article: Are Wall Street analysts’ stock ratings worth following?

Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.